As pharmaceutical companies rethink where and how critical molecules are sourced, India’s next opportunity may not be low-cost chemistry — but reliable, complex chemistry at scale.
For decades, pharmaceutical sourcing was largely driven by three questions:
Can you make the molecule? Can you meet the specification? Can you deliver it at the right cost?
In 2026, another question has moved rapidly up the agenda:
Can we depend on you?
Geopolitical uncertainty, medicine shortages, concentration of upstream manufacturing, changing regulatory expectations and the lessons of recent supply-chain disruptions are forcing pharmaceutical companies to rethink how they source APIs, intermediates, key starting materials and specialised fine chemicals.
The result is a shift that goes considerably deeper than the phrase “China+1.”
Global pharma is not simply looking for another low-cost manufacturing geography. It is looking for resilient chemistry partnerships. And that creates an important opportunity for India.
China+1 Is Evolving Into Supply-Chain Resilience
China remains deeply embedded in the global pharmaceutical and chemical supply chain and will continue to be an important manufacturing base. The change is not necessarily about replacing China — it is about avoiding excessive dependence on any single geography, supplier or manufacturing route.
Europe offers a clear indication of this changing thinking. The European Commission’s Critical Medicines Act, proposed in March 2025, includes measures intended to strengthen medicine security through greater manufacturing capacity, strategic partnerships and diversification of supply chains where dependence on a limited number of countries creates vulnerability.
That distinction is important. The next phase of pharmaceutical sourcing is increasingly about de-risking, rather than simply relocating.
For fine-chemical and intermediate manufacturers, this changes the basis of competition. Lowest price may secure a transaction. Reliability, chemistry capability and supply continuity can secure a relationship.
India’s Opportunity Is Getting Bigger
India already occupies a major position in global pharmaceuticals. India’s pharmaceutical exports reached approximately US$31.1 billion in FY2025–26, roughly double their level a decade earlier, with Indian medicines now reaching more than 200 countries.
The momentum is continuing. During April–June 2026, India’s pharmaceutical exports increased 6.8% year-on-year. Particularly relevant to the upstream pharmaceutical ecosystem, exports of bulk drugs and drug intermediates grew 13.84%, according to Pharmexcil data reported in August 2026.
The direction is encouraging. However, there is another side to the story.
The Indian Pharma Paradox
India is one of the world’s most important pharmaceutical manufacturing locations, yet remains significantly dependent on imported upstream materials.
In FY2024–25, India imported approximately US$4.35 billion of APIs, bulk drugs and drug intermediates. China accounted for approximately 73.7% of these imports.
That is more than a trade statistic. It reveals one of the largest strategic opportunities available to India’s pharmaceutical and chemical industries.
If India can progressively build deeper capabilities across:
Key Starting Materials → Advanced Intermediates → APIs → Formulations
it can strengthen its own pharmaceutical security while simultaneously becoming a more important partner to global pharmaceutical companies seeking diversified supply chains.
Government initiatives are already attempting to accelerate this transition. By March 2026, India’s PLI Scheme for bulk drugs had helped establish approximately 56,800 metric tonnes of annual domestic manufacturing capacity across 28 of 41 identified critical products.
But building capacity alone will not determine who wins. The bigger question is: what will global pharmaceutical customers expect from their next generation of chemistry partners?
1. From Molecule Supply to Chemistry Capability
If a molecule is widely available from multiple manufacturers, purchasing decisions can quickly become price-driven. Complex chemistry changes the equation.
Consider projects involving multi-step synthesis, boronic acids and esters, complex coupling reactions, acetylenic chemistry, Grignard chemistry, highly reactive reagents, demanding temperature conditions, difficult impurity profiles, or challenging scale-up requirements.
Here, customers are not simply purchasing kilograms of material. They are purchasing scientific capability and problem-solving ability. The valuable supplier of the future will increasingly be the organisation capable of answering “we have a difficult chemistry problem — can you solve it?” rather than simply “do you have this CAS number?”
2. Scale-Up Will Become a Differentiator
A synthesis that works beautifully at gram scale does not automatically become a commercially viable manufacturing process. Moving from laboratory chemistry to kilo and eventually multi-tonne manufacturing introduces entirely new variables.
Heat transfer changes. Mixing changes. Impurity profiles can change. Raw-material variability becomes important. Safety considerations become more complex. Yield losses that appear insignificant in a laboratory can dramatically alter commercial economics at manufacturing scale.
This is why the ability to connect Research → Process Development → Kilo Lab → Pilot Scale → Commercial Manufacturing is becoming strategically important. Pharmaceutical companies increasingly benefit from chemistry partners capable of staying with a molecule through multiple stages of its development, rather than repeatedly transferring knowledge between disconnected vendors.
3. Quality Is Moving Beyond the Certificate of Analysis
Historically, quality conversations could become overly focused on whether a shipment passed the final specification. That remains essential — but global customers increasingly require much more: process understanding, raw-material controls, analytical capability, impurity management, documentation, change control, equipment qualification, in-process monitoring, reproducibility, and continuous improvement.
In other words: quality cannot simply be tested into the final product — it has to be engineered into the process.
For pharmaceutical supply chains operating across multiple countries, this becomes even more important. A customer must be confident not just that Batch 1 will meet specifications, but that Batch 20 and Batch 50 can do so consistently as well.
4. Reliability Is Becoming Part of Quality
There is another definition of quality that pharmaceutical procurement teams are increasingly forced to consider: can the material actually be supplied when it is needed?
A molecule that achieves 99.9% analytical purity but arrives months after the required manufacturing window may still create significant downstream disruption. This is why the industry conversation is moving from pure efficiency toward resilience.
Manish Jain, Director of Naprod Life Sciences, captured the change succinctly in Express Pharma in May 2026, describing the need to shift away from a purely just-in-time manufacturing model toward one that also plans for contingency.
The statement reflects a broader change in pharmaceutical supply-chain thinking. Companies increasingly need to balance inventory efficiency with capacity preparedness, alternative sources, shorter response times and continuity planning. Supplier performance will increasingly be judged through a broader equation:
Quality + Consistency + Delivery + Continuity = Reliability
5. Transparency Could Become a Competitive Advantage
Global pharmaceutical companies are also asking more questions about what exists behind their immediate supplier. Where does the starting material originate? Is there a single-source dependency several layers upstream? Can alternative raw-material sources be qualified? How quickly can manufacturing volumes be increased? Which process steps represent potential bottlenecks? What happens if a critical reagent becomes unavailable?
This requires suppliers to understand more than their own factory — they increasingly need visibility into the supply network surrounding their chemistry. The strongest partnerships will therefore be built not merely around manufacturing capability, but around openness regarding risk and preparedness. In the future, transparency may become as valuable as price competitiveness.
6. Complex Outsourcing Makes Trust More Important
As pharmaceutical outsourcing moves upstream into research, custom synthesis, route development and proprietary intermediates, companies are sharing increasingly sensitive information with their chemistry partners — chemical structures, proprietary synthetic routes, impurity information, analytical methods, development timelines, scale-up challenges, and commercially sensitive product programmes.
The relationship therefore changes. The manufacturer is no longer merely a vendor — it can become an extension of the customer’s development organisation. Strong intellectual-property practices, confidentiality, documentation and an organisational culture built around customer trust therefore become critical differentiators.
India’s Bigger Opportunity: Move From Cost Advantage to Capability Advantage
India has spent decades building a formidable reputation for pharmaceutical manufacturing. But its next growth chapter could look different from the last one.
The country has the opportunity to strengthen its position in areas where customers value not merely manufacturing economics but specialised scientific and process capabilities — custom synthesis, complex fine chemicals, advanced pharmaceutical intermediates, process development, difficult-to-manufacture building blocks, scale-up chemistry, and specialised commercial manufacturing.
That shift matters because competing primarily on price inevitably creates downward pressure on margins. Competing on specialised capability creates something more defensible: expertise that is difficult to replace.
From Transactional Supplier to Strategic Chemistry Partner
This ultimately may be the most significant change taking place.
The traditional fine-chemical relationship often began with: “Here is the specification. Please quote.”
Tomorrow’s relationship may increasingly begin with: “Here is the chemistry challenge. How should we solve it?”
That creates an entirely different partnership. Instead of evaluating suppliers only against price-per-kilogram, customers begin considering: Can this partner understand our chemistry? Can they develop the process? Can they solve scale-up problems? Can they maintain impurity control? Can they manufacture repeatedly? Can they respond when requirements change? Can we trust them with a programme that may continue for years?
That is a much higher bar. It is also a much bigger opportunity.
Where Denisco Fits Into This Changing Landscape
This changing global requirement closely aligns with the model Denisco has built over the past 25 years.
Headquartered in Hyderabad, India, Denisco specialises in custom synthesis, fine chemicals and advanced intermediates, with capabilities spanning research, process development and manufacturing. Its chemistry expertise includes boronations, Suzuki/Stille/Heck coupling reactions, acetylenic chemistry, large-scale Grignard chemistry, halogenations, oxidations, reductions, alkylations, diazotisations and cyanations, including reactions across specialised temperature ranges.
Denisco’s portfolio includes more than 300 building blocks, with manufacturing capability ranging from kilo quantities to multi-tonne levels and more than 30 products manufactured under exclusive synthesis arrangements. Its customers span Western Europe, North America, Japan and India.
Its R&D organisation also works on route development, process optimisation and scaling products from laboratory through production — an increasingly important capability as customers look for partners who can accompany molecules through multiple development stages.
But the larger opportunity extends beyond Denisco. It is an opportunity for India’s entire fine-chemical ecosystem.
Beyond China+1
India should be careful not to define its opportunity simply as “companies want an alternative to China.” That makes India’s advantage dependent on another country’s disadvantage.
A far more powerful proposition would be: “The world needs resilient, sophisticated and diversified chemistry capabilities. India can build them.”
China+1 may create the opportunity for a conversation. Cost competitiveness may help open the door. But what converts that opportunity into a five-year or ten-year customer relationship will be something different: chemistry expertise, process capability, quality, transparency, scalability, and reliability.
Because in the next generation of pharmaceutical supply chains, delivering the molecule may only be the starting point.
The real product will be certainty.
About Denisco
Denisco Chemicals is a Hyderabad-headquartered custom synthesis and fine-chemical company specialising in complex fine chemicals, advanced intermediates and contract development. With capabilities extending from R&D and process development through kilo-scale and multi-tonne manufacturing, Denisco works with customers across India and international markets.
